Preemptive management of epstein-barr virus reactivation after hematopoietic stem-cell transplantation

Transplantation

Volumn 87, Issue 8, 2009, Pages 1240-1245

  Ahmad, Imran ^a   Cau, Nguyen V ^a   Kwan, John ^a   Maaroufi, Younes ^b   Meuleman, Nathalie ^a   Aoun, Mickael ^a   Lewalle, Philippe ^a   Martiat, Philippe ^a   Crokaert, Françoise ^b   Bron, Dominique ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Centre de Diagnostic Moleculaire   (Belgium)

Author keywords

Epstein Barr virus; Hematopoietic stem cell transplantation; Posttransplant lymphoproliferative disease

Indexed keywords

RITUXIMAB; VIRUS DNA; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION; APLASTIC ANEMIA; DRUG EFFECT; GENETICS; LEUKEMIA; LYMPHOMA; METHODOLOGY; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; PHYSIOLOGY; SURVIVAL; SURVIVOR; VIRUS ACTIVATION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA; LYMPHOMA; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; SURVIVORS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 65549101043     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819f1c49     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients.MMWRRecomm Rep 2000; 49(RR- 10): 1, CE1.
2. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155.
3. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non- HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377.
4. Harris NL, Swerdlow SH, Frizzera G, et al. Post-transplant lymphoproliferative disorders In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press 2001, p 264.
5. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94: 2208.
6. Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104: 1661.
7. Trappe RU, Choquet S, Reinke P, et al. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: The role of singleagent rituximab. Transplantation 2007; 84: 1708.
8. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053.
9. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549.
10. Popa C, Leandro MJ, Cambridge G, et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46: 626.
11. Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008; 58: 5.
12. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein- Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364.
13. Gärtner BC, Schäfer H, Marggraff K, et al. Evaluation of use of Epstein- Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol 2002; 40: 351.
14. Weinstock DM, Ambrossi GG, Brennan C, et al. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: An approach in development. Bone Marrow Transplant 2006; 37: 539.
15. Meerbach A, Wutzler P, Häfer R, et al. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 2008; 80: 441.
16. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein- Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37: 132.
17. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell- depleted SCT. Blood 2001; 98: 972.
18. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virusDNAload in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001;97: 1165.
19. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibodymediated T-cell depletion. Am J Transplant 2005; 5: 465.
20. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619.
21. Hakim H, Gibson C, Pan J, et al. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. J Clin Microbiol 2007; 45: 2151.
22. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979.